PORCINE DELTACORONAVIRUS (PDCoV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
OVERVIEW
Porcine deltacoronavirus (PDCoV) is a member of the genus Deltacoronavirus first detected in US swine in February 2014, causing acute watery diarrhea and mortality in suckling pigs similar to but generally milder than PEDV and TGEV. PDCoV RNA had been detected retrospectively in Chinese pigs in 2012 surveillance samples, but its pathogenic role was unclear until clinical US outbreaks were investigated. The virus has since spread to Canada, Mexico, multiple Asian countries (Korea, China, Thailand, Vietnam, Japan, Taiwan, Laos), and South America (Peru). From 2014-2024, 244 PDCoV outbreaks were recorded in US breeding herds affecting 186 individual sites. Notably, PDCoV demonstrates broader host range than other swine coronaviruses, with documented experimental infection of calves, poultry, and rodents. Most significantly for zoonotic assessment, viral RNA was identified in plasma of three children with mild febrile illness in Haiti—the only swine coronavirus with documented potential human infection.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Despite detection of PDCoV nucleic acids in human samples from Haiti, no foodborne transmission to humans has been documented or implicated. The Haitian pediatric cases presented with respiratory and febrile illness rather than enteric disease, and food consumption was not identified as a transmission route in case investigations. PDCoV remains primarily an enteric pathogen of swine with no established foodborne risk to humans through pork consumption or handling of pork products.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
PDCoV is the only swine coronavirus with documented evidence of potential human infection. Viral RNA was identified in plasma samples of three children aged 6-7 years presenting with mild symptoms including fever, cough, and abdominal pain during surveillance in Haiti in 2014-2015. While detailed epidemiological investigation was limited and the significance of these findings remains debated, they suggest PDCoV can occasionally infect humans—a capacity not demonstrated for TGEV, PRCV, PEDV, or pHEV. Experimental studies support broader host range: PDCoV successfully infects bovine cells and causes clinical disease in experimentally inoculated calves, replicates in chicken embryos and causes intestinal lesions in poultry, and infects mice. The virus does not rely exclusively on species-specific receptors like porcine aminopeptidase N (pAPN) that would restrict cross-species transmission. These collective findings place PDCoV in a distinctly higher zoonotic concern category than other swine coronaviruses, warranting continued surveillance even though human infection appears rare under current conditions.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission
PDCoV transmission is primarily fecal-oral through contaminated feces, vomitus, and environmental surfaces. Similar to PEDV, contaminated equipment, transport vehicles, personnel, and potentially feed ingredients can serve as transmission vehicles introducing virus to naive farms despite biosecurity measures intended to prevent direct animal contact. The virus demonstrates similar environmental persistence characteristics to other enteric coronaviruses, surviving in fecal material and on contaminated surfaces for extended periods under appropriate temperature and humidity conditions. Diverse PDCoV genotypes coexist in China, suggesting multiple independent introduction events or sustained regional circulation through various transmission pathways. There is no evidence supporting long-distance aerosol transmission as occurs with PRCV—PDCoV spread requires movement of contaminated materials or animals rather than airborne carriage. Transmission pathways can bypass direct pig contact but remain fundamentally dependent on fomite and contaminated material movement.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
PDCoV detection utilizes well-validated molecular and serological methods available through veterinary diagnostic laboratories. RT-PCR assays targeting conserved M or N gene regions are the standard diagnostic approach, with established multiplex assays differentiating PDCoV from PEDV, TGEV, SADS-CoV, and rotavirus in a single test. Next-generation sequencing enables comprehensive strain characterization and phylogenetic analysis. Immunofluorescence and immunohistochemistry using virus-specific antibodies detect antigen in intestinal tissues for histopathologic confirmation. Virus isolation in LLC-PK or ST cell lines with trypsin supplementation is possible for research purposes, though success rates may be lower than for PEDV. Serological assays including indirect immunofluorescence, virus neutralization, and various ELISA formats detect antibodies, with S1 protein-based assays preferred over N protein for specificity in avoiding cross-reactions. Clinical presentation overlaps substantially with PEDV and TGEV, requiring laboratory testing for definitive pathogen identification, but diagnostic tools are readily available and routinely applied.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence
PDCoV causes clinical disease similar to PEDV but with generally lower severity and mortality rates. Field observations during 2014 US outbreaks documented up to 40% mortality in suckling pigs, compared to 50-100% mortality typically reported for PEDV in naive herds. Outbreaks in China and Thailand caused 64-80% mortality in suckling pigs on severely affected farms, demonstrating that severe losses can occur. Clinical disease in older growing and finishing pigs is typically mild, transient, and self-limiting with minimal production impact. The annual incidence rate of PDCoV outbreaks in US breeding herds ranged from 0.44% to 4.28% across years (2014-2024), indicating ongoing but relatively limited circulation compared to the explosive 2013-2014 PEDV epidemic. PDCoV often co-circulates with PEDV in the same herds and geographic areas, complicating attribution of specific losses to each pathogen. The lower typical virulence compared to PEDV and the self-limiting nature of outbreaks once sow immunity develops place PDCoV in the manageable chronic losses category.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
PDCoV is not an OIE-listed disease and does not trigger international trade restrictions or affect export market access. The virus has now spread to multiple continents without prompting trade barriers between endemic countries. Detection of PDCoV on a farm or in a region does not result in movement restrictions, enhanced surveillance requirements, or certification complications for market hogs. Production losses from outbreaks are absorbed at the individual farm operation level without broader market supply disruption. Consumer awareness of PDCoV is essentially zero, and the disease poses no food safety concerns that would affect consumer demand or pork marketability.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
PDCoV is a viral pathogen carrying no antimicrobial resistance genes. The virus does not contribute to the AMR gene pool and poses no concerns regarding antimicrobial resistance development, carriage, or dissemination regardless of disease management approaches employed.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for PDCoV, so disease management does not involve antimicrobials targeting the primary pathogen. Management relies on supportive care for affected piglets and development of protective lactogenic immunity in breeding females through natural exposure (feedback protocols) or vaccination where available. Antibiotics may be used if secondary bacterial infections complicate recovery in severely affected litters, but uncomplicated PDCoV infection does not require or benefit from antimicrobial therapy. The emphasis on prevention through maternal immunity rather than therapeutic treatment means PDCoV infections generate minimal selection pressure for antimicrobial resistance.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific antiviral treatments exist for PDCoV infection. Management is entirely supportive: providing fluid and electrolyte support to address dehydration from diarrhea, maintaining thermal comfort for piglets, and ensuring nursing piglets have adequate access to colostrum and milk from immune sows. Treatment cannot alter the course of viral infection—interventions only support survival while host immune responses develop. Research into PDCoV molecular biology and host interactions continues for understanding pathogenesis, but no practical therapeutic approaches are available or in advanced development for field application.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No commercial PDCoV vaccines are currently available in the United States or most other affected countries. One published experimental study demonstrated that an inactivated adjuvanted PDCoV vaccine administered to pregnant gilts induced maternal virus-neutralizing antibodies that transferred to colostrum and milk, reducing diarrhea incidence in challenged nursing piglets (12.9% vs. 100% in control litters). However, this experimental vaccine has not progressed to commercial development and licensure. Control of PDCoV in affected breeding herds currently relies entirely on feedback protocols—intentional exposure using infected intestinal material to build natural sow immunity before farrowing. The relatively lower economic impact of PDCoV compared to PEDV, combined with the technical success of feedback approaches for herd immunity, has limited commercial incentive for vaccine development and introduction.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
PDCoV can be eliminated from individual farms through controlled exposure to establish uniform sow immunity, strict biosecurity implementation, and management approaches similar to those used for PEDV elimination. The virus is less widespread in US swine than PEDV, with 244 recorded breeding herd outbreaks over 10 years (2014-2024) affecting 186 sites—a more limited distribution than the extensive PEDV circulation established during 2013-2014. However, PDCoV's demonstrated broader host range—with documented experimental infection of cattle, poultry, and rodents in addition to pigs—creates additional reservoir and maintenance concerns not present for PEDV or TGEV. Multiple distinct genotype lineages coexist globally, suggesting ongoing viral evolution and potential for continued introductions. Farm-level elimination is achievable with standard coronavirus control approaches, but regional or national eradication would require addressing potential non-swine reservoirs, maintaining biosecurity against feed and transport reintroduction pathways, and sustained coordinated industry-wide effort exceeding what has been achieved for any swine coronavirus to date.